Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co.

Recursion Pharmaceuticals (NASDAQ:RXRX) had its price objective lowered by JPMorgan Chase & Co. from $11.00 to $10.00 in a research report report published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Bank of America reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.20.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $3.46 on Thursday. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.82 billion, a PE ratio of -2.34 and a beta of 1.02. Recursion Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.18. The company’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $4.20.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07. The company had revenue of $35.54 million during the quarter, compared to analyst estimates of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company’s revenue was up 671.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.53) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals will post -0.93 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Ben R. Taylor sold 7,956 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the transaction, the chief financial officer owned 1,180,318 shares in the company, valued at $4,001,278.02. The trade was a 0.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $3.35, for a total value of $94,798.30. Following the transaction, the chief executive officer directly owned 2,262,085 shares in the company, valued at approximately $7,577,984.75. This represents a 1.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 299,680 shares of company stock valued at $1,180,121 over the last quarter. Corporate insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $31,000. Integral Investment Advisors Inc. acquired a new position in Recursion Pharmaceuticals during the 1st quarter valued at about $39,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $41,000. MQS Management LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, Allworth Financial LP grew its position in shares of Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.